PL327626A1 - Antagonists of vitronectin receptor - Google Patents

Antagonists of vitronectin receptor

Info

Publication number
PL327626A1
PL327626A1 PL96327626A PL32762696A PL327626A1 PL 327626 A1 PL327626 A1 PL 327626A1 PL 96327626 A PL96327626 A PL 96327626A PL 32762696 A PL32762696 A PL 32762696A PL 327626 A1 PL327626 A1 PL 327626A1
Authority
PL
Poland
Prior art keywords
antagonists
vitronectin receptor
vitronectin
receptor
Prior art date
Application number
PL96327626A
Other languages
English (en)
Inventor
Fadia E Ali
William E Bondinell
Richard M Keenan
Thomas Wen Ku Ku
William H Miller
James Sammanen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PL327626A1 publication Critical patent/PL327626A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL96327626A 1995-12-29 1996-12-20 Antagonists of vitronectin receptor PL327626A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US936795P 1995-12-29 1995-12-29

Publications (1)

Publication Number Publication Date
PL327626A1 true PL327626A1 (en) 1998-12-21

Family

ID=21737218

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96327626A PL327626A1 (en) 1995-12-29 1996-12-20 Antagonists of vitronectin receptor

Country Status (14)

Country Link
US (1) US6159964A (OSRAM)
EP (1) EP0906103A1 (OSRAM)
JP (1) JP2000502704A (OSRAM)
KR (1) KR19990076877A (OSRAM)
CN (1) CN1209063A (OSRAM)
AU (1) AU1295597A (OSRAM)
BR (1) BR9612381A (OSRAM)
CZ (1) CZ203898A3 (OSRAM)
IL (1) IL125030A0 (OSRAM)
NO (1) NO983001L (OSRAM)
PL (1) PL327626A1 (OSRAM)
TR (1) TR199801254T2 (OSRAM)
WO (1) WO1997024124A1 (OSRAM)
ZA (1) ZA9610854B (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds
JP2000502708A (ja) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
JP2000508319A (ja) * 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αvβ3拮抗薬
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
US6239138B1 (en) * 1997-07-25 2001-05-29 Smithkline Beecham Corporation Vitronectin receptor antagonist
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
DE69919334T2 (de) 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
BR9908636A (pt) * 1998-03-10 2002-01-08 Smithkline Beecham Corp Antagonistas de receptor vitronectina
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
SE9803773D0 (sv) * 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
KR20010093303A (ko) 1999-02-20 2001-10-27 플레믹 크리스티안 β-알라닌 유도체
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CN1374863A (zh) 1999-07-21 2002-10-16 惠氏公司 αvβ3整联蛋白的双环选择性拮抗剂
DE19939980A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
GB9929988D0 (en) * 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
DE10028402A1 (de) * 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
AU2001267753A1 (en) 2000-07-07 2002-01-21 Celltech R And D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
CA2419255A1 (en) * 2000-08-29 2002-03-07 Ish Kumar Khanna Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
IL154496A0 (en) * 2000-08-30 2003-09-17 Pharmacia Corp GEM-SUBSTITUTED alpha v beta3 INTEGRIN ANTAGONISTS
US6531494B1 (en) * 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6472372B1 (en) * 2000-12-06 2002-10-29 Ortho-Mcneil Pharmaceuticals, Inc. 6-O-Carbamoyl ketolide antibacterials
KR100376088B1 (ko) * 2001-03-09 2003-03-28 주식회사 태평양 3-아미노프로필코질포스페이트 및 그의 염을 함유한미백화장료 조성물
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 TNFα를 이용한 병용 요법
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
RU2004117082A (ru) 2001-12-05 2005-04-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Кетолидные 6-0-ацил-производные эритромицина в качестве антибактериальных средств
GB0130341D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
AU2004276522B2 (en) 2003-09-26 2010-12-02 Merck Serono Sa Leader sequences for use in production of proteins
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
WO2007079199A2 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
EP2101805B1 (en) 2007-01-18 2012-11-07 Merck Patent GmbH Integrin ligands for use in treating cancer
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
MX2010006972A (es) 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
CA2763099A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
MX2011012491A (es) 2009-05-25 2011-12-14 Merck Patent Gmbh Administracion continua de cilengitida en tratamientos contra el cancer.
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
EP3956309A4 (en) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450707A (en) * 1966-12-13 1969-06-17 Sterling Drug Inc Certain 2-anilino-pyridine derivatives
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
JPH08505145A (ja) * 1992-12-21 1996-06-04 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
ZA9610853B (en) * 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.

Also Published As

Publication number Publication date
EP0906103A1 (en) 1999-04-07
KR19990076877A (ko) 1999-10-25
EP0906103A4 (OSRAM) 1999-04-07
AU1295597A (en) 1997-07-28
BR9612381A (pt) 1999-07-13
CN1209063A (zh) 1999-02-24
WO1997024124A1 (en) 1997-07-10
US6159964A (en) 2000-12-12
IL125030A0 (en) 1999-01-26
CZ203898A3 (cs) 1999-03-17
TR199801254T2 (xx) 1998-10-21
NO983001D0 (no) 1998-06-26
NO983001L (no) 1998-08-26
ZA9610854B (en) 1998-04-02
JP2000502704A (ja) 2000-03-07

Similar Documents

Publication Publication Date Title
PL327626A1 (en) Antagonists of vitronectin receptor
PL327694A1 (en) Antagonists of vitronectin receptor
PL327919A1 (en) Antagonists of vitronectin receptors
PL318199A1 (en) Antagonists of vitronectin receptors
ZA955391B (en) Vitronectin receptor antagonists
CY2576B1 (en) Vitronectin receptor antagonists
PL334499A1 (en) Antagonists of vitronectin receptors
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
EP1000031A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS
PL339381A1 (en) Antagonists of vitronectin receptor
IL135189A0 (en) Vitronectin receptor antagonist
IL135188A0 (en) Vitronectin receptor antagonist
IL118299A0 (en) Pharmacological use of AII-receptor antagonists
PL320638A1 (en) Antagonists of endothein receptors
ZA968093B (en) Additional antagonists of endothelin receptors
HK1019196A (en) Vitronectin receptor antagonists
SI0957917T1 (sl) Antagonisti receptorja vitronektina
ZA988562B (en) Vitronectin receptor antagonists
HK1012358A (en) Vitronectin receptor antagonists
HK1031115A (en) Vitronectin receptor antagonists
HK1026694A (en) Vitronectin receptor antagonists